Science TechnologyTuesday, 19 May 2026·Hindu Tamil Thisai
India introduces 7-minute subcutaneous Tecentriq injection for NSCLC treatment
Roche Pharma India has introduced Tecentriq, a subcutaneous immunotherapy injection that can be administered in about 7 minutes for non-small cell lung cancer patients in India.
Key highlights
Direct fact
In May 2026, Roche Pharma India introduced Tecentriq in India as a subcutaneous immunotherapy injection for non-small cell lung cancer (NSCLC), with administration time of about 7 minutes.
Key specifics
- Tecentriq is the brand name used for the new injection introduced by Roche Pharma India.
- The treatment is designed for non-small cell lung cancer (NSCLC), the most common lung cancer type mentioned in the report.
- The injection is given under the skin and takes about 7 minutes, unlike long intravenous (IV) sessions.
- One dose costs about ₹3.7 lakh, according to the report.
- Up to 6 doses may be required for many patients during treatment.
Exam lens
Question type: Science & technology match-the-following, cancer therapy, immunotherapy vs chemotherapy, Tecentriq, Roche Pharma India, 7 minutes, ₹3.7 lakh. TNPSC may ask which new cancer treatment was introduced in India and what makes it different from IV therapy.